Skip to content
OpenCapital
Get started

Karyopharm Therapeutics KPTI Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$35.1MBeat by $3.7M
EPS-$1.24Beat by $0.21
Revenue estimate$31.4M
EPS estimate-$1.45

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$33.6M
EPS estimate-$1.31

Versus estimates

Revenue

Q1 2026$35.1MBeat by $3.7M
Q4 2025$34.1MMiss by $1.0MQ3 2025$44.0MBeat by $2.0MQ2 2025$37.9MMiss by $1.6MQ1 2025$30.0MMiss by $5.1MQ4 2024$30.5MMiss by $7.3M

Diluted EPS

Q1 2026-$1.24Beat by $0.21
Q4 2025-$3.60Miss by $1.34Q3 2025-$3.82Miss by $0.35Q2 2025-$4.32Miss by $0.52Q1 2025-$2.77Beat by $1.44Q4 2024-$3.60Beat by $0.30

Ask the moment Karyopharm Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Karyopharm Therapeutics report Q1 2026 earnings?
Karyopharm Therapeutics (KPTI) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Karyopharm Therapeutics's Q1 2026 revenue and EPS?
Karyopharm Therapeutics reported revenue of $35.1M and eps of $-1.24 for Q1 2026.
Did Karyopharm Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $31.4M by $3.7M. EPS beat the consensus estimate of $-1.45 by $0.21.
How did Karyopharm Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.8% from $30.0M a year earlier and eps grew 55.2% from $-2.77.
Where can I find Karyopharm Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-222808) and the 10-Q periodic report (0001193125-26-222827) directly on SEC EDGAR. The filing index links above go to sec.gov.